LncRNA ASB16-AS1 drives proliferation, migration, and invasion of colorectal cancer cells through regulating miR-185-5p/TEAD1 axis. Issue 1 (2nd January 2022)

• Record Type: Journal Article
• Authors: Yu, Mingxu; Shi, Changsheng; Xu, Dingyin; Lin, Xingcheng; Ji, Tingting; Shi, Zhengchao; Zhuge, Xiaoju; Zhuo, Shengye; Yang, Qing
• Is Part Of: Cell cycle. Volume 21:Issue 1(2022)
• Page Start: 1
• Page End: 11
• Publication Date: 2022-01-02
• Subjects: ASB16-as1 -- miR-185-5p -- tead1 -- colorectal cancer; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2021.1973700
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: As a common malignant tumor, colorectal cancer (CRC) has a high incidence. Recent investigations have suggested that although great improvement has been achieved in the survival rate of early-stage CRC patients, the overall survival rate remains low. Mounting reports have proved that lncRNAs take part in the development of various cancers and possess the regulatory functions in cancers. For example, ASB16 antisense RNA 1 (ASB16-AS1) is a poorly researched novel lncRNA whose specific functions in CRC are still unknown. In our research, we discovered that ASB16-AS1 was with high expression in CRC cells. In addition, ASB16-AS1 silencing restrained the proliferation, migration, invasion, and stemness while accelerating cell apoptosis of CRC cells. Mechanism experiments were applied to explore the regulatory mechanism of ASB16-AS1. It turned out that miR-185-5p could interact with ASB16-AS1 and inhibited the progression of CRC cells. TEAD1 (TEA domain transcription factor1) - a major effector of the Hippo signaling was proved to serve as the target of miR-185-5p and promote CRC development. In short, ASB16-AS1 drove the progression of CRC through the regulation of miR-185-5p/TEAD1 axis.